GTS Securities’s Revance Therapeutics, Inc. RVNC Stock Holding History

GTS Securities’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-22,590	Closed	-$68.7K	–	1666
2024 Q4	$68.7K	Buy	+22,590	New	+$98.4K	﹤0.01%	1180
2024 Q3	–	Sell	-10,908	Closed	-$54.2K	–	4519
2024 Q2	$28K	Sell	10,908 -28,736	-72%	-$98.1K	﹤0.01%	3763
2024 Q1	$195K	Sell	39,644 -3,103	-7%	-$18.4K	﹤0.01%	3353
2023 Q4	$376K	Buy	+42,747	New	+$350K	﹤0.01%	3020
2023 Q3	–	Sell	-11,024	Closed	-$212K	–	4173
2023 Q2	$279K	Buy	+11,024	New	+$343K	0.01%	925

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GTS Securities's RVNC Position: Q1 2025 in Review

GTS Securities sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 22,590 shares — an estimated $68.7K sold.

GTS Securities first reported a position in RVNC in Q2 2023 and held it in 5 quarters. The position peaked at $376K in Q4 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

GTS Securities reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
GTS Securities sold 22,590 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $68.7K.
GTS Securities first reported a position in Revance Therapeutics, Inc. in Q2 2023 and held it in 5 quarters.
GTS Securities's Revance Therapeutics, Inc. position peaked at $376K in Q4 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on GTS Securities's 13F filing for Q1 2025, filed 15 May 2025.